Among the specific topics commanding healthcare professionals' (HCP) attention were the potential for Sanofi’s Dupixent in eosinophilic esophagitis, Amgen’s tezepelumab in uncontrolled asthma, and Lilly’s Olumiant in atopic dermatitis.

During Q4 earnings calls, biopharmaceutical companies reflected on the cumulative impact of the COVID-19 pandemic. An assessment of US-based physician sentiment (n=62) provides a useful ‘on-the-ground’ perspective to further examine these issues.

On International Women's Day, ZoomRxers #ChooseToChallenge any gender bias at the workplace. We commit to bringing about change and accelerating gender parity at the workplace.

Across multiple indications, physicians anticipate 2021 will be an exciting year for advancing treatments across autoimmune and auto-inflammatory conditions.In a study conducted by ZoomRx late December 2020, 107 practicing U.S. rheumatologists

Andrew Yukawa is a Consultant in our San Francisco office. His willingness to both learn from his teammates and his generosity in sharing his own skills have made him a key member of

Having weathered many challenges in Q2 2020, biopharmaceutical firms, by and large, presented a case for optimism during Q3 2020 earnings calls. However, alongside this optimistic outlook were a number of voices expressing

Uma Sankar is a Software Development Lead in our Chennai office. She’s been at ZoomRx for over four years and has worked in software development for seven. Uma’s deep understanding of

Oncologists are growing accustomed to attending the field’s major meetings virtually, with AACR, ASCO, and now ESMO 2020 having gone fully digital.While the virtual format has undoubtedly impacted attendees’ experiences and

A return to pre-pandemic levels of in-person promotional activity looks increasingly uncertain in H2 2020. Given this uncertainty, pharmaceutical manufacturers, from diversified, multinational firms to more focused, growth-stage companies are navigating the complexities

Oncologists often develop individualized treatment plans to ensure patients are receiving care tailored to their situation. Here are factors influencing their decisions.

Despite the disruption and transition to a completely virtual format, 2020 was not an off-year for ASCO. Nearly all oncologists who attended this year’s ASCO Annual Meeting felt that it represented at

Pharmaceutical manufacturers, from diversified, multinational firms to focused, growth-stage companies are adapting to the reality of COVID-19. Recent Q1 investor calls provide insight into both the impact of the pandemic thus far on

With the ASCO 2020 Annual Meeting just days away, oncologists are nearly universally planning to “attend” this year’s virtual meeting. However, their participation in the meeting will be less in real-time and

Often, traditional research doesn't answer all questions pertaining to clinical treatment decisions. Here's ZoomRx's new approach to address such questions.